|1.||Hromec, J: 1 article (09/2010)|
|2.||Krcméry, S: 1 article (09/2010)|
|3.||Gábrisová, Z: 1 article (09/2010)|
|4.||Tahotný, R: 1 article (09/2010)|
|5.||Bunnag, Chaweewan: 1 article (12/2003)|
|6.||Assanasane, Paraya: 1 article (12/2003)|
|7.||Jareoncharsri, Perapun: 1 article (12/2003)|
|8.||Tunsuriyawong, Prayuth: 1 article (12/2003)|
|9.||Voraprayoon, Siriporn: 1 article (12/2003)|
|10.||Pinkaew, Bangon: 1 article (12/2003)|
|1.||Respiratory Tract Infections (Respiratory Tract Infection)
03/01/2000 - "Comparison of the first study period (first course of LW 50020 and drug-free interval) with the second study period (second course of LW 50020 and follow-up) showed an overall reduction of at least 50% in the number, severity, and duration of respiratory tract infections, the number of antibiotic and symptomatic treatments, and the number of days absent from school or work. "
12/01/2003 - "An open-label, non-comparative study was performed in the Department of Otolaryngology, Siriraj Hospital, Bangkok, Thailand, to assess the safety, tolerability, acceptability and efficacy of an oral polyvalent bacterial lysate (Luivac) in the treatment of recurrent respiratory tract infections (RTIs) in Thai patients. "
03/01/2000 - "This multicenter, open study, carried out in 14 countries in Europe, Latin America, and Asia, recruited 4965 patients suffering from recurrent respiratory tract infections to investigate the safety and acceptability of the oral bacterial lysate immunomodulator LW 50020. "
12/01/2003 - "An open-label, prospective study of an oral polyvalent bacterial lysate (Luivac) in the treatment of recurrent respiratory tract infections in Thai patients."
11/01/1998 - "A comparison of the infection rates in the first and second study periods of patients treated with LW 50020 revealed a placebo-corrected reduction of 39% in children and a placebo-corrected reduction of 44% in adolescents and adults. "
09/01/2010 - "The authors compare immunomodulators Urovaxom and Luivac as part ofa combined immunotherapy and chemoprophylaxis regimens with small doses of fluorochinolones over 12 months in women with recurrent urinary infections. "
|2.||Immunologic Factors (Immunomodulators)